DOCSLIB.ORG

Increasing Blood Flow Rate; a Tool to Improve Adequacy of Dialysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Increasing Blood Flow Rate; a Tool to Improve Adequacy of Dialysis ORIGINAL ARTICLE ISRA MEDICAL JOURNAL | Volume 9 - Issue 6 | Nov - Dec 2017 Increasing Blood Flow Rate; A Tool To Improve Adequacy Of Dialysis Aurangzeb Afzal1, Maira Iqbal Malik2, Adnan Shabbir2 ABSTRACT OBJECTIVE: To assess the effect of increasing blood flow rate on the adequacy of dialysis, and to prove that increased blood flow can be helpful in achieving adequate dose of dialysis, in patients having low efficiency of dialysis . STUDY DESIGN: Quasi experimental study PLACE AND DURATION: At Dialysis unit of Lahore General Hospital over a period of 1 month from 28th January to 28th February 2017. METHODOLOGY: A total of 40 patients on regular hemodialysis participated in this study. Hemodialysis was performed at two different blood flow speeds 300 and 350 ml/min. Blood samples were obtained just before start and 45 minutes after completion of dialysis to measure urea levels. Urea Reduction Ratio (URR) was used as an index of dialysis dose and hence dialysis efficiency. RESULT: Increasing blood flow rate from 300 to 350ml/min has a significant impact on URR and hence on dialysis adequacy. It was observed that increasing blood flow rate from 300ml/min to 350ml/min raised URR from 53% to 60%. Marked statistical difference in URR between the two groups that is 7% was observed using the paired T-test. P value was 0.001 (<0.05). CONCLUSION: Increasing blood flow rate (BFR) has been successful in boosting effective dose of dialysis and is likely to prove beneficial for patients requiring hemodialysis. KEYWORDS: Hemodialysis, Adequacy, Blood Flow Rates, Low Efficiency, Urea reduction ratio. HOW TO CITE THIS: Afzal A, Malik MI, Shabbir A. Increasing Blood Flow Rate; A Tool To Improve Adequacy Of Dialysis. Isra Med J. 2017; 9(6): 399-401 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. INTRODUCTION whereby waste and excess water are removed from the blood and is a cornerstone of renal replacement therapy. During Being a lifesaving procedure, adequate dialysis confers health hemodialysis, small solute particles are removed by diffusion in patients with end stage renal disease dependent on dialysis. whereas convection is involved in the removal of larger Patients with end stage kidney disease need dialysis for particles. Factors such as membrane thickness, temperature, survival.1 Adequate dialysis is essential to enhance quality of flow rate of blood and dialysate affect the process of diffusion.4 life and increase lifespan. Dialysis is thus targeted at decreasing A Urea Reduction Ratio (URR) of 65% or higher has been morbidity and prolonging life. Mortality and morbidity of proven to improve outcome in dialysis patients.5,6 Increase in patients can be decreased by effective hemodialysis2 and blood flow rate (BFR), dialysate flow rate, duration of dialysis when not effective, can lead to increased number of deaths. and use of high quality dialyzers are some of the methods that A study was performed by Sehgal and his colleagues where can increase URR7,8 but all these cannot be implemented due the cost of inadequate dialysis was assessed and a conclusion to economic barriers.6 Bearing this is mind and keeping the was drawn that ineffective dialysis led to prolonged hospital other factors constant, this study was planned and performed stay and increased treatment cost. Thus, decrease in expense to monitor the extent to which change in flow rate of blood of treatment and improvement in health of patients can be affected the process of diffusion and hence the urea reduction brought about by adequate dialysis.3 Dialysis is a process ratio (URR) which was used as a measure of dialysis dose.5,6 Urea level of blood before and after dialysis was used to 1. Head of Department of Nephrology, calculate URR. Dialysis duration cannot be always increased Lahore General Hospital. due to intolerance of patients. Use of advanced filters means 2. Post Graduate Resident increase in cost of procedure. Also, the outcome of increase in Department of Medicine dialysate flow rate is usually short lived. This study was thus Lahore General Hospital. carried out to monitor a variable that would be feasible to apply and would be more cost effective.7,8. Thus keeping the Correspondence to: other factors constant, it aimed at observing the improvement Dr. Aurangzeb Afzal in dialysis efficacy with increase in flow rate of blood (BFR). The Head of Department of Nephrology, objective of our study was to assess the effect of increasing Lahore General Hospital. blood flow rate on the adequacy of dialysis, and to prove that E-mail: [email protected] increased blood flow can be helpful in achieving adequate dose of dialysis, in patients having low efficiency of dialysis. Received for Publication: 26-04-17 Accepted for Publication: 04-10-17 399 Aurangzeb Afzal et al. ISRA MEDICAL JOURNAL | Volume 9 - Issue 6 | Nov - Dec 2017 METHODOLOGY was found between increased blood flow rate and increase in URR. If we compare mean URR between two groups it went This quasi experimental study was carried out over a period of from 0.53 (53%) at blood flow 300 to 0.60 (60%) by increasing 1 month (January 28th to February 28th 2017) at Dialysis Unit of blood flow to 350 ml/min (Table-II). P value was 0.001 (less Lahore General Hospital. A total of 40 patients (25 Males, 15 than 0.05). This increase in urr is very significant. Females) aged 18-65 on regular hemodialysis participated in the study. Complete information about the study was provided TABLE-I: FREQUENCY OF SEX AND BIOCHEMICAL PARAME- to all the patients and they were included only after their full TERS OF DIALYSIS PATIENTS INCLUDED IN THE STUDY (N=40) consent. None of the participant patients dropped out. Only Variable Frequency Percentage the patients who were registered with the dialysis unit, those having arterio-venous fistulas, on twice weekly maintenance Male 25 62.5% dialysis lasting for 4 hours each, dependent on dialysis for Female 15 37.5% more than a year and those who had ample tolerability to Hep B positive 3 7.5% dialysis were included in the study. Whereas patients with double lumen catheters, on emergency hemodialysis (not Hep C positive 18 45% maintenance) and hemodynamically unstable patients HTN 20 50% unable to tolerate high flow rates were not included in the DM 6 15% study. Age, weight, height and serum albumin level of all Blood Flow 300 40 100% the patients was noted down. Presence of co-morbidities such as diabetes mellitus, hypertension, chronic liver disease Blood Flow 350 40 100% (CLD) was also made note of from clinical record by a team TABLE-II: COMPARISON OF URR AT TWO DIFFERENT BLOOD member. The dialysis machines were checked for proper FLOW SPEEDS IN DIALYSIS PATIENTS (N=40) functioning. A Fresenius model 4008S dialysis machine was used for every patient. Data from each patient was collected GROUP STATISTICS in two parts. In the first session, blood flow rate was set at Std. Std. 300ml/min (group - 1) and then at 350ml/min (group - 2) in the Groups N Mean Devia- Error next session of dialysis. In every patient, blood samples were tion Mean taken right before and 45minutes after each dialysis session. Group-I 40 .53070 .082584 .013058 A team member was designated for sampling, delivering and URR collecting blood samples to laboratory. Urea level in blood Group-II 40 .60060 .057139 .009035 was measured and recorded each time. Validity of collected data was constantly checked. Urea Reduction Ratio (URR) was an index of dialysis dose and hence dialysis efficiency. In this study, dialysis adequacy was monitored at two separate blood flow speeds. It was calculated using the standard formula (pre. dialysis urea – post. dialysis urea /pre. dialysis urea x 100). Data Analysis: We statistically analyzed data from both groups to observe change in URR by changing blood flow using t-test. Body weight of all patients was recorded prior to and after dialysis. Patients were constantly monitored during each session for hemodynamic stability. The collected data was analyzed using the SPSS 23.0 software, t-test was used to compare data between two groups. P-value <0.05 was considered statistically significant. RESULTS FIGURE – 1: MEAN URR IN THE TWO STUDY GROUPS. (N=40) A total of 40 patients were included in the study. Regarding the gender distribution of patients in the group, 62.5% (N=25) DISCUSSION were men and 37.5% were women [Table - I]. The largest proportion (50%) was formed by people aged between 41-60 Comparing this data with analogous studies9-12, there was clear years of age and only 10% was formed by people of 60 years evidence that efficiency of dialysis in our center was not up to and above. Only 15% had a history of diabetes mellitus and 50% the mark but marked improvement was seen by increasing flow of the patients were hypertensive [Table I]. Results show that rate of blood during dialysis. Kim and his colleagues performed increasing blood flow rate has a significant impact on URR and a study and demonstrated that effectiveness of dialysis can hence on dialysis adequacy. Paired t test was used to compare be ameliorated by raising BFR by 15-20%.13 Renal failure and the data between two groups. Comparison was made between end stage renal disease are some of the most prevalent health mean URR of group 1(blood flow rate 300 ml/min) and group problems we are facing today.
Load more

Recommended publications
  • Guidelines for Contributing Authors
    Charuhas V. Thakar, MD, FASN, FNKF Editor-in-Chief Professor of Medicine Director, Division of Nephrology Kidney C.A.R.E. Program (Clinical Advancement, Research & Education) 231 Albert B Sabin Way Cincinnati, OH 45267 Email: [email protected] Phone: 513-558-5471 Samantha Kramer, Managing Editor Email: [email protected] Guidelines for Contributing Authors Mission Statement The purpose of Advances in Chronic Kidney Disease (ACKD) is to provide in-depth, scholarly review articles about the care and management of persons with early kidney disease and kidney failure, as well as those at risk for kidney disease. Emphasis is on articles related to the early identification of kidney disease; prevention or delay in progression of kidney disease; the multidisciplinary case management of patients with chronic kidney disease or kidney failure; organ effects of kidney disease; epidemiology and outcomes research in kidney disease; benefits and complications of the primary treatment methods, dialysis and transplantation; technical aspects of the delivery of uremia therapy; care of the critically ill patient with kidney failure in the intensive care setting; new therapies for kidney failure; and health care research in chronic kidney disease. The full spectrum of basic science through clinical care is covered in these reviews. Clinical care issues stress the multidisciplinary team approach to the care of kidney patients. Topics covered will be of interest to practicing nephrologists (pediatric and adult), nephrology fellows (pediatric and adult), nurses, technicians, dieticians, and social workers caring for patients with kidney disease. Each issue of ACKD includes a focused review section of several articles on a topic of current interest.
    [Show full text]
  • Dialysis Dosing: Kinetics Versus Physiology
    Dialysis Dosing: Kinetics Versus Physiology KDIGOMaría F. Slon Complejo Hospitalario Navarra Navarra, Spain Disclosure of Interests • NxStage European Medical Advisory Board KDIGO KDIGO Controversies Conference on Dialysis Initiation, Modality Choice & Prescription January 25-28, 2018 | Madrid, Spain Epidemiology Estimated number of patients undergoing RRT from 2010 to 2030 worldwide (A) and by region (B) KDIGO Liyanage T, et al. Lancet 2015 Epidemiology Expected remaining lifetime (years) of the general population (cohort 2011-2015) and of prevalent dialysis and transplant patients (cohort 2011-2015) KDIGO ERA-EDTA Registry Annual Report 2015 Epidemiology Unadjusted percentages of deaths in 2014 by cause, excludes missing/unknown causes of death data among dialysis patients Cardiovascular disease > 50% KDIGO Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute myocardial infarction; CHF, congestive heart failure; CVA, cerebrovascular accident. USRDS Annual Data Report 2017 Dialysis Therapy SOLUTES CLEARANCE Uremic Toxins HORMONE PRODUCTION Electrolites Regulation Red blood cell mass Acid–base Balance regulation Calcium–phosphate Vitamin D regulation control KDIGO Others VOLUME HOMEOSTASIS Fluid Overload Blood pressure control Dialysis Therapy SOLUTES CLEARANCE Convetional Uremic Toxins Hemodialysis Electrolites Regulation Acid–base Balance Peritoneal dialysis Calcium–phosphate control KDIGO Hemodiafiltration technologies VOLUME HOMEOSTASIS Intensive Hemodialysis Fluid Overload Blood pressure control Ability for solute clearance,
    [Show full text]
  • Abbreviations
    Abbreviations AAPCC Adjusted average per capita cost CKD-EPI chronic kidney disease epidemiology calculation ACEI angiotensin-converting enzyme inhibitor CKO cytokinin oxidase ACR albumin/creatinine ratio CMS Centers for Medicare & Medicaid Services ADL activities of daily living CMV cytomegalovirus (antibody status) ADR annual data report COPD chronic obstructive pulmonary disease AF atrial fibrillation CORR Canadian Organ Replacement Register AFIB atrial fibrillation CPM clinical performance measures AFS Annual Facility Survey (CMS 2744) CPRA calculated panel reactive bodies AJKD American Journal of Kidney Disease CPT current procedure and terminology AKI acute kidney injury CrCl creatinine clearance rate AKI-D acute kidney injury with dialysis CROWNWeb Consolidated Renal Operations in a Web- AMI acute myocardial infarction Enabled Network (CROWN) Data — data collection system for ESRD dialysis ANZDATA Australia & New Zealand ESRD database facilities mandated by CMS ARB angiotensin receptor blocker CRT cardiac resynchronization ASHD atherosclerotic heart disease CVA cerebrovascular accident AV arteriovenous CVD cardiovascular disease BMI body mass index CVVHD continuous venous-to-venous hemodialysis BUN blood urea nitrogen CWF common working file CABG coronary artery bypass grafting DCD donation after circulatory death CAPD continuous ambulatory peritoneal dialysis DCI Dialysis Clinic, Inc. CBC complete blood count DFC dialysis facility compare CCPD continuous cycling peritoneal dialysis DGF delayed graft function CDC Centers for Disease
    [Show full text]
  • Perspectives of Dialysis Patients
    Department of Health and Human Services OFFICE OF INSPECTOR GENERAL “KNOW YOUR N(JMBER” BROCHURE PERSPECTIVES OF DIALYSIS PATIENTS JUNE GIBBS BROWN Inspector General JANUARY 1997 OEI-06-95-O0320 OFFICE OF INSPECTOR GENERAL The mission of the OffIce of Inspector General (OIG), as mandated by Public Law 95-452, is to protect the integrity of the Department of Health and Human Services programs as well as the health and welfare of beneficiaries served by them. This statutory mission is carried out through a nationwide program of audits, investigations, evaluations, sanctions, and fraud alerts. The Inspector General informs the Secretary of program and management problems and recommends legislative, regulatory, and operational approaches to correct them. OFFICE OF EVALUATION AND INSPECTIONS The OIG’S OffIce of Evaluation and Inspections (OEI) conducts short-term management and program evaluations (called inspections) that focus on issues of concern to the Department, the Congress, and the public. The inspection reports provide findings and recommendations on the efficiency, vulnerability, and effectiveness of departmental programs. OEI’S Dallas Regional Oftlce prepared this report under the direction of Chester B. Slaughter, Regional Inspector General. Project staff included: DALLAS REGION HEADQUARTERS Michelle Adams, Ph. D. Mary Beth Clarke Ruth Ann Dorrill Brian Ritchie Karen Erickson, Intern Barbara Tedesco Sarah Taylor Judy Tyler Nancy Watts For additional copies of this report, please contact the Dallas Regional OffIce at (800) 848-8960. Department of Health and Human Services OFFICE OF INSPECTOR GENERAL “KNOW YOUR NUMBER” BROCHURE PERSPECTIVES OF DIALYSIS PATIENTS $‘o + JUNE GIBBS BROWN Inspector General ‘+4b dza # J~ARY 1997 OEI-06-95-O0320 EXECUTIVE SUMMARY PURPOSE This study describes the perspectives of end stage renal disease (ESRD) patients regarding the effectiveness of the Health Care Financing Administration’s (HCFA) “Know Your Number” brochure in educating them about a way to monitor the adequacy of their dialysis.
    [Show full text]
  • Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate
    الجامعةةةةةةةةةةةةةةةةةةةةة اﻹسةةةةةةةةةةةةةةةةةةةة مية بغةةةةةةةةةةةةةةةةةةةة زة The Islamic University of Gaza عمةةةةةةاحة البحةةةةةةد العلمةةةةةةي والد اسةةةةةةا العليةةةةةةةا Deanship of Research and Graduate Studies كليةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةة العلةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةو Faculty of Science Master of Biological Sciences ماجسةةةةةةةةةةةةةةةةةةتير العلةةةةةةةةةةةةةةةةةةو الحياتيةةةةةةةةةةةةةةةةةةةة Medical Technology التحةةاليةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةل الطبيةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةةة Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate سيستاتين سي وبعض المعايير البيوكيميائية لقياس كفاءة الغسيل الدموي لدى مرضى الفشل الكلوي المزمن في مستشفى الشفاء - محافظة غزة Prepared By Fawwaz H. Eliglah Supervisor Prof. Baker M. Zabut Faculty of Science Biochemistry Department The Islamic University of Gaza A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biological Sciences- Medical Technology September , 2018 إقةةةةةةةةةةةةةةرا أنا الموقع أحناه مقد الرسالة التي تحمل العنوان: Cystatin C and Some Biochemical Parameters for Dialysis Adequacy Among Hemodialysed Patients at Al-Shifa Hospital, Gaza-Governorate سيستاتين سي وبعض المعايير البيوكيميائية لقياس كفاءة الغسيل الدموي لدى ي مرضى الفشل الكلو المزمن في مستشفى الشفاء - محافظة غزة أقر بأن ما اشتملت عليه هذه الرسالة إنما هو نتاج جهدي الخاص، باستثناء ما تمت اﻹشارة إليه حيثما ورد، وأن هذه الرسالة ككل أو أي جزء منها لم يقدم من قبل اﻻخرين لنيل درجة أو لقب علمي أو بحثي لدى أي مؤسسة تعليمية أو بحثية أخرى. Declaration I understand the nature of plagiarism, and I am aware of the University’s policy on this. The work provided in this thesis, unless otherwise referenced, is the researcher's own work, and has not been submitted by others elsewhere for any other degree or qualification. اسم الطالب: فواز حسن العجلة :Student's name التوقيع: Signature: Fawwaz H.
    [Show full text]
  • Manual of Clinical Dialysis
    Manual of Clinical Dialysis Second Edition Manual of Clinical Dialysis Second Edition Suhail Ahmad University of Washington, Scribner Kidney Center, Northwest Kidney Centers, Seattle, Washington, USA ABC Suhail Ahmad, MD Professor, Medicine University of Washington Scribner Kidney Center Northwest Kidney Centers Seattle, Washington [email protected] ISBN: 978-0-387-09650-6 e-ISBN: 978-0-387-09651-3 DOI: 10.1007/978-0-387-09651-3 Library of Congress Control Number: 2008928866 °c Springer Science+Business Media, LLC 2009 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper springer.com Grateful thanks to my family, Vimli, Saba, and Zeba, and friends for their strong support and to Arlene for all of her help.
    [Show full text]
  • Kt/V Calculations for the Assessment of Hemodialysis Adequacy
    Wt 0.10 0.08 0.06 0.04 1.80 0.02 0.00 1.60 1.40 Kt/V 1.20 1.00 0.80 0.60 0.40 0.50 0.60 0.70 0.80 URR We have found that the Keshaviah Quick Kt/V formula most closely correlates with both of the more complex Kt/V calculations that Spectra offers - the Daugirdas II Natural Log and Depner Full UKM Kt/V (see Figures 2 & 3). Comparison of Kt/V Formulas to UKM Kt/V Comparison of Kt/V Formulas to UKM Kt/V 1500 Patient Results 0.6 to 2.0 2.20 2.20 2.00 2.00 1.80 1.80 1.60 1.60 1.40 1.40 1.20 Kt/V Calculations for 1.00 1.20 0.80 1.00 0.60 the Assessment of 0.40 1 4 7 0.80 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93 95 97 99 101 103 105 107 109 111 113 115 117 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61 64 67 70 73 76 79 82 85 88 91 94 97 112 115 118 100 103 106 109 121 Hemodialysis Adequacy Depner Full UKM Depner Full UKM Daugirdas II (Post BUN/Pre BUN-0.008 x t) + Daugirdas II (Post BUN/Pre BUN-0.008 x t) + Natural Log [4-3.5 x (Post BUN/Pre BUN)] x UF / Wt Natural Log [4-3.5 x (Post BUN/Pre BUN)] x UF / Wt Jindal 0.04*URR-1.2 Jindal 0.04*URR-1.2 Basile 0.023*URR-0.284 Basile 0.023*URR-0.284 Depner 0.026*URR-0.49 Depner 0.026*URR-0.49 Keshaviah 1.162*In(Pre/Pst) Keshaviah 1.162*In(Pre/Pst) Figure 2 Figure 3 References 1 Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error.
    [Show full text]
  • Urea Reduction Ratio (URR) for Dialysis
    Urea Reduction Ratio or URR How do I know I am getting the right amount of dialysis? The correct amount of dialysis to clear waste products from your body is called dialysis adequacy. The health care team uses many ways to find out if you are having adequate dialysis. How should I feel? When your dialysis therapy is adequate, you should have more energy. You should also sleep better and feel like eating. When your dialysis therapy needs adjusting, you may feel weak and tired. You may not sleep well. You may not feel like eating or may have an upset stomach. You may also have some swelling in the ankles or feet or have problems breathing. What is URR? One way to assess dialysis adequacy is to do a blood test called Urea Reduction Ratio or URR. This test measures a waste product called urea. A blood sample is taken before and after the dialysis treatment through the dialysis machine. The laboratory then tests the blood for urea. The results come back as a percentage of urea lowered during the dialysis treatment. The Dialysis Units do URR blood tests once a month on all dialysis patients. Your dialysis therapy will aim to give you a URR of 65% or more - the higher the number the better. This means the hemodialysis treatments are working well to get rid of waste products in your body. If your blood test result is below 65%, the doctor will assess your dialysis prescription and improve your URR. Each person will have a number that the doctor feels is right for that person.
    [Show full text]
  • Management of Hypertension for Patients Undergoing Dialysis Therapy Yoshihiro Taniyama
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Taniyama Renal Replacement Therapy (2016) 2:21 DOI 10.1186/s41100-016-0034-2 REVIEW Open Access Management of hypertension for patients undergoing dialysis therapy Yoshihiro Taniyama Abstract Hypertension is very prevalent among patients undergoing dialysis therapy: hemodialysis (HD) and peritoneal dialysis (PD). Although it is recognized as a great risk of cardiovascular mortality for these populations, how to regulate blood pressure (BP) is poorly understood. For HD patients, we should pay much attention to methods of measuring BP. Out- of-center BP levels and BP variability should be evaluated by ambulatory BP monitoring and home BP measurement because they are closely associated with cardiovascular mortality. Although target BP levels are not clear, several clinical guidelines suggest <140/90 mmHg. However, it must be determined for each individual patient with careful considerations about comorbidities. Based on the underling pathophysiology of hypertension in patients on dialysis, maintaining an appropriate volume of body fluid by dietary salt restriction and optimization of dry weigh should be considered as a first line therapy. Inhibitors for renin-angiotensin system may be suitable to reduce BP and mortality for those patients on dialysis. These drugs may also be effective for preserving residual renal function and peritoneal function for PD patients. β-blockers may have potentials to improve survival for HD patients and can be added to anti- hypertensive medications. Lacking large-scale and good quality clinical trials, there are many questions to be answered. Much effort should continuously be made to create evidences for better management of hypertension for patients on dialysis therapy.
    [Show full text]
  • Dialyzers and Dialysis Adequacy
    Dialyzers and Dialysis Adequacy NANT National Symposium February 10th, 2009 Las Vegas, Nevada Jim Curtis, CHT Home Dialysis Plus Portland, Oregon “The dialyzer is where the tire meets the road”... Peter Lepanto DIALYZER CHARACTERISTICS Membrane Material – Biocompatibility Solute Removal - Clearance – Diffusion – Convection – Adsorption Dialyzer Membranes Cellulose Synthetic Cuprophan PAN Cupromonium Rayon AN 69 Hemophan PMMA Cellulose Acetate Polysulphone Cellulose Triacetate Polyflux Purema BIOCOMPATIBILITY The choice of membrane material affects how the blood will react when in contact with the membrane Reactions to Bioincompatability Indicators of Bioincompatability Reactions to Bioincompatability Mild / unnoticed DAA Severe - anaphylactic shock INDICATORS OF BIOINCOMPATABILITY Compliment activation – increase in circulating C3a level – Decrease in white blood cells Hyper coagulation COMPLIMENT ACTIVATION C3a Baseline WBC’s TIME SOLUTE REMOVAL Diffusion Convection Adsorption Dialyzer Clearance Clearance (K) specifications for dialyzers indicate the amount of a specific Solute will be “cleared” from the patients blood in a given amount of time For example, if the specs say a dialyzer has a clearance of 350 ml/min at a Qb of 400 ml/min, it means that in one minute 350 ml’s of blood will be cleared of urea, and the remaining 50 ml/min will have the same amount of urea that it started with Solute Removal: Diffusion In diffusion, molecules move from an area of high concentration to an area of low concentration. The higher the concentration gradient, the more rapid the diffusion Diffusive clearances are dependant upon: – blood flow rates – dialysate flow rates – membrane surface area Solute Removal: Convection Also known as “Solute Drag”, molecules move with the fluid as it crossed the membrane.
    [Show full text]
  • Factors That Affect Postdialysis Rebound in Serum Urea Concentration, Including the Rate of Dialysis: Results from the HEMO Study
    J Am Soc Nephrol 15: 194–203, 2004 Factors that Affect Postdialysis Rebound in Serum Urea Concentration, Including the Rate of Dialysis: Results from the HEMO Study JOHN T. DAUGIRDAS, TOM GREENE, THOMAS A. DEPNER, JOHN LEYPOLDT, FRANK GOTCH, GERALD SCHULMAN, and ROBERT STAR for the Hemodialysis (HEMO) Study Group National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland Abstract. Previous studies have suggested that postdialysis was the strongest predictor of rebound among 22 factors con- urea rebound is related to K/V, the rate of dialysis, but a sidered. Other factors associated with greater rebound for 1331 systematic analysis of factors that affect rebound has not been patients using AV accesses or venous catheters included access reported. With the use of 30-min and, in a subset, 60-min type, black race, male gender, absence of congestive heart postdialysis samples, postdialysis urea rebound was measured failure, greater age, ultrafiltration rate, and low predialysis or to (1) determine how well previously proposed equations based intradialysis systolic BP. Equations of the form eKt/V ϭ on the rate of dialysis (K/V) predict rebound in a large sample single-pool Kt/V Ϫ B ϫ (K/V) were fit to the data. With AV of patients with varying characteristics, (2) determine whether access, the optimum values for the slope term (B) were 0.39 other factors besides K/V affect rebound, and (3) estimate and 0.46 (in hϪ1) for single-pool Kt/V calculated based on 20-s more precise values for coefficients in prediction equations for postdialysis or immediate postdialysis samples, respectively.
    [Show full text]
  • Hemodialysis Dose and Adequacy
    Hemodialysis Dose and Adequacy When kidneys fail, dialysis is neces­ The amount of urea removed (35 mg/dL) sary to remove waste products such as is expressed as a percentage of the pre- urea from the blood. By itself, urea is dialysis urea level (50 mg/dL). only mildly toxic, but a high urea level 35/50 = 70/100 = 70% means that the levels of many other waste products that are more harm­ Although no fixed percentage can be ful and not as easily measured are also said to represent an adequate dialysis, building up. patients generally live longer and have fewer hospitalizations if the URR is To see whether dialysis is removing at least 60 percent. As a result, some enough urea, the dialysis clinic should experts recommend a minimum URR periodically—normally once a month— of 65 percent. test a patient’s blood to measure dialysis adequacy. Blood is sampled at the start The URR is usually measured only once of dialysis and at the end. The levels of every 12 to 14 treatments, which is urea in the two blood samples are then once a month. The URR may vary con­ compared. Two methods are generally siderably from treatment to treatment. used to assess dialysis adequacy, URR Therefore, a single value below 65 per­ and Kt/V. cent should not be of great concern, but a patient’s average URR should exceed What is the URR? 65 percent. URR stands for urea reduction ratio, meaning the reduction in urea as a What is the Kt/V? result of dialysis.
    [Show full text]